Non-dilutive strategic transaction expected to extend cash runway into 2029, to advance Compugen's innovative immuno-oncology pipeline and to reach potential key catalysts from internal and partnered programs Monetization includes an upfront payment of $65 million and a potential additional $25 million upon reaching the next milestone Compugen retains majority of royalties preserving potential significant long-term upside reflecting its belief in the potential of rilvegostomig HOLON, Israel, Dec

PADCEV plus Keytruda is the first and only regimen without platinum-based chemotherapy to improve event-free and overall survival when used before and after surgery in cisplatin-eligible patients with muscle-invasive bladder cancer Positive EV-304 data, combined with the recent unprecedented results from the EV-303 trial, highlight the potential of this combination to become a new platinum-free standard of care in an earlier stage of bladder cancer Results from the Phase 3 EV-304 trial will be

– Vir Biotechnology to receive EUR 55 million initial reimbursement payment upon closing, and up to EUR 495 million in clinical, regulatory and sales milestones, along with tiered, mid-teen to high-twenties percent royalties on net sales – Companies to share clinical development costs for ongoing ECLIPSE registrational program with Norgine contributing approximately 25% of go-forward external costs – ECLIPSE 3, designed to support access and reimbursement in Europe and other key geographies, has

AXINON® LDLp Test System receives Medical Device Authority (MDA) in Malaysia numares Health appoints BioD Medica for local distribution MDA filing for additional CE-marked product is currently in progress REGENSBURG, Germany, Dec. 17, 2025 /PRNewswire/ -- numares Health ("numares"), the transformative metabolomics company pioneering multidimensional biomarker insights that deliver clinical pathways for optimal patient care, today announces the expansion of its global footprint into the ASEAN re

Agreement underscores Norgine's mission to bring innovative therapies to patients and builds on our heritage in hepatology and specialty pharmaceuticals. Vir Biotechnology's chronic hepatitis delta treatment candidate has shown robust virological responses and reflects a differentiated approach to treatment. UXBRIDGE, England, Dec. 17, 2025 /PRNewswire/ -- Norgine, a leading European specialty pharmaceutical company, today announced an exclusive licensing agreement under which Norgine will comme

Hansa Biopharma said Tuesday that its IgG-targeting treatment candidate has failed a late-stage study in a rare type of kidney disease due to an overperforming control arm. The Swedish biotech’s imlifidase plus standard of care did not significantly improve kidney function as measured by estimated glomerular filtration rate at six months versus SOC alone. The SOC is plasma exchange, the immunosuppressive drug cyclophosphamide, and glucocorticoids. The Phase 3 trial enrolled 50 adults with anti-g

Hansa Biopharma announced that a pivotal study evaluating its antibody-cleaving enzyme imlifidase in anti-glomerular basement membrane (anti-GBM) disease failed to meet the main goal of slowing down renal function decline. The news sent the company's shares down as much as 20% on Wednesday.The Phase III GOOD-IDES-02 trial enrolled 50 adults, of whom half received imlifidase followed by protocol-defined standard of care (SoC) comprising immediate, intensive plasma exchange, cyclophosphamide and g

Merck & Co. announced Wednesday that another Phase III trial investigating the combination of its PD-1 checkpoint inhibitor Keytruda (pembrolizumab) with Pfizer and Astellas' antibody-drug conjugate (ADC) Padcev (enfortumab vedotin) in muscle-invasive bladder cancer (MIBC) met its primary endpoint, as well as key secondary goals, including overall survival (OS).The KEYNOTE-B15/EV-304 study randomised 808 patients with MIBC who are eligible for cisplatin-based chemotherapy to receive perioperativ

Bristol Myers Squibb entered into a multi-year collaboration and licence agreement with Harbour BioMed, potentially worth up to $1.125 billion, to discover and develop next-generation multispecific antibodies.The collaboration will leverage Harbour’s proprietary Harbour Mice platform — which can generate fully human traditional two heavy and two light chains (H2L2) as well as heavy chain only (HCAb) monoclonal antibodies — to build the multispecific assets. The alliance may also utilise Harbour’

The first regulatory win for Cytokinetics' cardiac myosin inhibitor aficamten anywhere in the world came Wednesday in China, where the drug – locally branded as Myqorzo – will be marketed by Sanofi. The treatment is indicated to improve exercise capacity and symptoms in adults with New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy (oHCM). The decision comes days before a closely watched FDA ruling expected by Dec. 26 (see – Spotlight On: Key PDUFA dates to wa